Remibrutinib is the first Bruton tyrosine kinase inhibitor approved by the FDA for chronic spontaneous urticaria.

Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who ...

Investing.com -- Novartis (NYSE:NVS) has received FDA approval for Rhapsido (remibrutinib), the first oral Bruton’s tyrosine kinase inhibitor (BTKi) treatment for chronic spontaneous urticaria (CSU) ...

The FDA today approved remibrutinib (Rhapsido; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for the treatment of chronic spontaneous urticaria (CSU) in patients who remain ...

(Reuters) -The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the Swiss drugmaker said on Tuesday. The twice-daily ...

The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday. The twice-daily pill, Rhapsido, is ...

On September 30, 2025, Novartis announced that its drug Rhapsido® (remibrutinib) received FDA approval as the first oral Bruton’s tyrosine kinase inhibitor (BTKi) for treating chronic spontaneous ...

A honeybee hive, with its large stores of pollen, wax, and honey, is like a fortress guarding treasure: with strong defenses, but a bonanza for enemies that can overcome those. More than 30 parasites ...

Omalizumab is indicated for the treatment of persistent asthma, chronic rhinosinusitis with nasal polyps, food allergies and chronic spontaneous urticaria.

As Bob Faulkner suited up in his protective bee attire for his semi-weekly visit to the SU beehives, he explained the importance of bees.

Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous blockbuster drug. Read why REGN is a Buy.